Charles River Laboratories (CRL)
Charles River Laboratories International, Inc. is a healthcare company listed on the New York Stock Exchange under the ticker CRL. The company provides services and products used in drug discovery, non-clinical development, and safety testing in the United States, Europe, Canada, the Asia Pacific, and other international markets. Its Research Models and Services segment supplies rodents and purpose-bred rats and mice, and also supports research model use through genetically engineered models, insourcing solutions, diagnostic services, and cell therapy development and production. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery work, preclinical safety assessment services, and vivarium space. The Manufacturing Solutions segment provides quality control testing, specialized biologics testing, and contract development and manufacturing services. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company also maintains strategic collaborations with Parker Institute for Cancer Immunotherapy, Children’s Hospital Los Angeles, and the Francis Crick Institute.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-CRL
|
$222.01
|
0.5% Upside
|
Fair
|
$230.93
|
4.5% Upside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-57.4x
|
3.6x
|
2.6x
|
10.582 B
|
13.301 B
|
22.4%
|
98.9%
|
3.2
|
—
|
-211.9%
|